These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31578170)

  • 1. Interstitial lung disease: perhaps unclassifiable, but not untreatable.
    Oldham JM
    Lancet Respir Med; 2020 Feb; 8(2):126-127. PubMed ID: 31578170
    [No Abstract]   [Full Text] [Related]  

  • 2. Unclassifiable interstitial lung disease: A review.
    Skolnik K; Ryerson CJ
    Respirology; 2016 Jan; 21(1):51-6. PubMed ID: 26059704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneity in Unclassifiable Interstitial Lung Disease. A Systematic Review and Meta-Analysis.
    Guler SA; Ellison K; Algamdi M; Collard HR; Ryerson CJ
    Ann Am Thorac Soc; 2018 Jul; 15(7):854-863. PubMed ID: 29779392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease.
    Solomon JJ; Danoff SK; Goldberg HJ; Woodhead F; Kolb M; Chambers DC; DiFranco D; Spino C; Haynes-Harp S; Hurwitz S; Peters EB; Dellaripa PF; Rosas IO;
    Adv Ther; 2019 Nov; 36(11):3279-3287. PubMed ID: 31515704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical profile of unclassifiable interstitial lung disease: Comparison with chronic fibrosing idiopathic interstitial pneumonias.
    Traila D; Oancea C; Tudorache E; Mladinescu OF; Timar B; Tudorache V
    J Int Med Res; 2018 Jan; 46(1):448-456. PubMed ID: 28758849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unclassifiable interstitial lung diseases: Clinical characteristics and survival.
    Hyldgaard C; Bendstrup E; Wells AU; Hilberg O
    Respirology; 2017 Apr; 22(3):494-500. PubMed ID: 28297158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Combined Therapy with Pirfenidone and Erythromycin for Unclassifiable Interstitial Pneumonia Induced by HTLV-1-associated Bronchioloalveolar Disorder (HABA).
    Yokohori N; Sato A; Hasegawa M; Katsura H; Hiroshima K; Takemura T
    Intern Med; 2017; 56(1):73-78. PubMed ID: 28050003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.
    Hyldgaard C
    Dan Med J; 2015 Apr; 62(4):B5069. PubMed ID: 25872544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and prognosis of unclassifiable interstitial lung disease.
    Ryerson CJ; Urbania TH; Richeldi L; Mooney JJ; Lee JS; Jones KD; Elicker BM; Koth LL; King TE; Wolters PJ; Collard HR
    Eur Respir J; 2013 Sep; 42(3):750-7. PubMed ID: 23222877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unclassifiable interstitial lung disease: from phenotyping to possible treatments.
    Guler SA; Ryerson CJ
    Curr Opin Pulm Med; 2018 Sep; 24(5):461-468. PubMed ID: 30004990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
    Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
    BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and prognosis of unclassifiable interstitial lung disease.
    Troy L; Glaspole I; Goh N; Zappala C; Hopkins P; Wilsher M; Moodley Y; Corte T
    Eur Respir J; 2014 May; 43(5):1529-30. PubMed ID: 24789954
    [No Abstract]   [Full Text] [Related]  

  • 13. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
    Tashkin DP; Roth MD; Clements PJ; Furst DE; Khanna D; Kleerup EC; Goldin J; Arriola E; Volkmann ER; Kafaja S; Silver R; Steen V; Strange C; Wise R; Wigley F; Mayes M; Riley DJ; Hussain S; Assassi S; Hsu VM; Patel B; Phillips K; Martinez F; Golden J; Connolly MK; Varga J; Dematte J; Hinchcliff ME; Fischer A; Swigris J; Meehan R; Theodore A; Simms R; Volkov S; Schraufnagel DE; Scholand MB; Frech T; Molitor JA; Highland K; Read CA; Fritzler MJ; Kim GHJ; Tseng CH; Elashoff RM;
    Lancet Respir Med; 2016 Sep; 4(9):708-719. PubMed ID: 27469583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unclassified or unclassifiable interstitial lung disease: confusing or helpful disease category?
    Cottin V; Wells A
    Eur Respir J; 2013 Sep; 42(3):576-9. PubMed ID: 24000249
    [No Abstract]   [Full Text] [Related]  

  • 15. Unclassifiable Interstitial Lung Disease: Time to Shrink the Black Box.
    Brown AW
    Ann Am Thorac Soc; 2018 Jul; 15(7):806-807. PubMed ID: 29957036
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease.
    Miura Y; Saito T; Fujita K; Tsunoda Y; Tanaka T; Takoi H; Yatagai Y; Rin S; Sekine A; Hayashihara K; Nei T; Azuma A
    Sarcoidosis Vasc Diffuse Lung Dis; 2014 Oct; 31(3):235-8. PubMed ID: 25363224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pirfenidone combined with corticosteroids in a patient with systemic lupus erythematosus-associated interstitial lung disease.
    Yang BB; Man XY; Zheng M
    J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):e388-e389. PubMed ID: 28261880
    [No Abstract]   [Full Text] [Related]  

  • 18. [Newly developed therapeutic drugs for idiopathic interstitial pneumonias].
    Azuma A
    Nihon Naika Gakkai Zasshi; 2006 Jun; 95(6):1069-75. PubMed ID: 16846057
    [No Abstract]   [Full Text] [Related]  

  • 19. Oxidative stress and antioxidants in interstitial lung disease.
    Bast A; Weseler AR; Haenen GR; den Hartog GJ
    Curr Opin Pulm Med; 2010 Sep; 16(5):516-20. PubMed ID: 20592594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unclassifiable-interstitial lung disease: Outcome prediction using CT and functional indices.
    Jacob J; Bartholmai BJ; Rajagopalan S; Egashira R; Brun AL; Kokosi M; Nair A; Walsh SLF; Karwoski R; Nicholson AG; Hansell DM; Wells AU
    Respir Med; 2017 Sep; 130():43-51. PubMed ID: 29206632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.